Počet záznamů: 1  

Inherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients

  1. 1.
    SYSNO ASEP0431922
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevInherited variability in a master regulator polymorphism (rs4846126) associates with survival in 5-FU treated colorectal cancer patients
    Tvůrce(i) Pardini, Barbara (UEM-P)
    Bermejo, J. L. (DE)
    Naccarati, Alessio (UEM-P)
    Di Gaetano, C. (IT)
    Rosa, F. (IT)
    Legrand, C. (DE)
    Novotný, J. (CZ)
    Vodička, Pavel (UEM-P) RID
    Kumar, R. (DE)
    Celkový počet autorů9
    Zdroj.dok.Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. - : Elsevier - ISSN 0027-5107
    766-767, AUG-SEP (2014), s. 7-13
    Poč.str.7 s.
    Jazyk dok.eng - angličtina
    Země vyd.NL - Nizozemsko
    Klíč. slovacolorectal cancer ; genome-wide association studies (GWAS) ; EQTL studies
    Vědní obor RIVEB - Genetika a molekulární biologie
    CEPGAP304/10/1286 GA ČR - Grantová agentura ČR
    GAP304/12/1585 GA ČR - Grantová agentura ČR
    Institucionální podporaUEM-P - RVO:68378041
    UT WOS000340321200002
    EID SCOPUS84902504926
    DOI10.1016/j.mrfmmm.2014.05.007
    AnotaceTreatment with 5-fluorouracil (5-FU) improves survival in many cancers including colorectal cancer. Response to the treatment, overall survival and recurrence show inter-individual variation. In this study we employed a strategy to search eQTL variants influencing the expression of alarge number of genes. We identified four single nucleotide polymorphisms, defined as master regulators of transcription, and genotyped them in a set of 218 colorectal cancer patients undergoing adjuvant 5-FU based therapy. The minor allele variant of the rs4846126 polymorphism was associated with poor overall and progression-free survival. Patients that were homozygous for the variant allele showed two fold increased risk of death (HR 2.20 95%CI 1.05–4.60) and progression (HR 2.88, 95%1.47–5.63). The integration of external information from publicly available gene expression repositories suggested that the rs4846126 polymorphism deserves further investigation. This variant potentially regulates the gene expression of 273 genes with some of them possibly associated to the patient’s responseto 5-FU treatment or colorectal cancer. Present results show that mining of public data repositories in combination with own data can be a fruitful approach to identify markers that affect therapy outcome. In particular, a genetic screen of master regulators may help to search for the polymorphisms involved in treatment responsein cancer patients.
    PracovištěÚstav experimentální medicíny
    KontaktLenka Koželská, lenka.kozelska@iem.cas.cz, Tel.: 241 062 218, 296 442 218
    Rok sběru2015
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.